Monday, September 30, 2024

Isocyanides inhibit bacterial pathogens by covalent targeting of essential metabolic enzymes

Alexandra Geißler, Howard Junca , Andreas M. Kany , Lena J. Daumann, Anna K. H. Hirsch  Dietmar H. Pieper b and Stephan A. Sieber 

Chem. Sci., 2024, 15, 11946-11955

 https://doi.org/10.1039/D4SC01940G

Isonitrile natural products, also known as isocyanides, demonstrate potent antimicrobial activities, yet our understanding of their molecular targets remains limited. Here, we focus on the so far neglected group of monoisonitriles to gain further insights into their antimicrobial mode of action (MoA). Screening a focused monoisonitrile library revealed a potent S. aureus growth inhibitor with a different MoA compared to previously described isonitrile antibiotics. Chemical proteomics via competitive cysteine reactivity profiling, uncovered covalent modifications of two essential metabolic enzymes involved in the fatty acid biosynthetic process (FabF) and the hexosamine pathway (GlmS) at their active site cysteines. In-depth studies with the recombinant enzymes demonstrated concentration-dependent labeling, covalent binding to the catalytic site and corresponding functional inhibition by the isocyanide. Thermal proteome profiling and full proteome studies of compound-treated S. aureus further highlighted the destabilization and dysregulation of proteins related to the targeted pathways. Cytotoxicity and the inhibition of cytochrome P450 enzymes require optimization of the hit molecule prior to therapeutic application. The here described novel, covalent isocyanide MoA highlights the versatility of the functional group, making it a useful tool and out-of-the-box starting point for the development of innovative antibiotics.



Expanding the Covalent Warhead Toolbox: Discovery of the First Covalent PARG Inhibitors Using Bicyclo[1.1.0]butane-Based Warheads

Olivier Querolle  and Luca Iacovino  and Andreas Goutopoulos  and Tian Jin  and Zaixu Xu  and Marta Malattia  and Nicolas Bocquet  and Alena...